Edition:
United States

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

3.58USD
19 Apr 2018
Change (% chg)

$0.08 (+2.14%)
Prev Close
$3.50
Open
$3.45
Day's High
$3.60
Day's Low
$3.45
Volume
6,723
Avg. Vol
13,493
52-wk High
$6.85
52-wk Low
$2.78

Chart for

About

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $111.73
Shares Outstanding(Mil.): 31.92
Dividend: --
Yield (%): --

Financials

  PRQR.OQ Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -2.14 -- --
ROI: -84.41 -0.75 13.17
ROE: -94.35 -2.86 14.98

BRIEF-Proqr Q4 Loss Per Share ‍Eur 0.39

* PROQR ANNOUNCES RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017 AND PROVIDES BUSINESS UPDATE

Feb 28 2018

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

Jan 08 2018

BRIEF-ProQR Receives Orphan Drug Designation From EMA For Drug Candidate Qr-313 For Dystrophic Epidermolysis Bullosa

* PROQR RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR DRUG CANDIDATE QR-313 FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Proqr reports loss of EUR 0.42 per share​

* Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​ Source text for Eikon: Further company coverage:

Nov 20 2017

BRIEF-ProQR doses first LCA 10 patient in clinical trial of QR-110

* ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness

Nov 13 2017

Earnings vs. Estimates